144 related articles for article (PubMed ID: 18362304)
1. Risk factors for post-treatment hypogonadism in testicular cancer patients.
Eberhard J; Ståhl O; Cwikiel M; Cavallin-Ståhl E; Giwercman Y; Salmonson EC; Giwercman A
Eur J Endocrinol; 2008 Apr; 158(4):561-70. PubMed ID: 18362304
[TBL] [Abstract][Full Text] [Related]
2. Inhibin B concentration is predictive for long-term azoospermia in men treated for testicular cancer.
Isaksson S; Eberhard J; Ståhl O; Cavallin-Ståhl E; Cohn-Cedermark G; Arver S; Lundberg Giwercman Y; Giwercman A
Andrology; 2014 Mar; 2(2):252-8. PubMed ID: 24519955
[TBL] [Abstract][Full Text] [Related]
3. Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.
Tandstad T; Solberg A; Håkansson U; Stahl O; Haugnes HS; Oldenburg J; Dahl O; Kjellman A; Angelsen A; Cohn-Cedermark G;
Acta Oncol; 2015 Apr; 54(4):493-9. PubMed ID: 25192551
[TBL] [Abstract][Full Text] [Related]
4. Testosterone deficiency in testicular cancer survivors - a systematic review and meta-analysis.
Bandak M; Jørgensen N; Juul A; Vogelius IR; Lauritsen J; Kier MG; Mortensen MS; Glovinski P; Daugaard G
Andrology; 2016 May; 4(3):382-8. PubMed ID: 27009402
[TBL] [Abstract][Full Text] [Related]
5. Sexual function in men treated for testicular cancer.
Eberhard J; Ståhl O; Cohn-Cedermark G; Cavallin-Ståhl E; Giwercman Y; Rylander L; Eberhard-Gran M; Kvist U; Fugl-Meyer KS; Giwercman A
J Sex Med; 2009 Jul; 6(7):1979-89. PubMed ID: 19453896
[TBL] [Abstract][Full Text] [Related]
6. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
7. Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality.
Eberhard J; Ståhl O; Cohn-Cedermark G; Cavallin-Ståhl E; Giwercman Y; Rastkhani H; Rylander L; Eberhard-Gran M; Kvist U; Giwercman A
J Affect Disord; 2010 May; 122(3):260-6. PubMed ID: 19656574
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
[TBL] [Abstract][Full Text] [Related]
9. Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment.
Pühse G; Secker A; Kemper S; Hertle L; Kliesch S
Int J Androl; 2011 Oct; 34(5 Pt 2):e351-7. PubMed ID: 21062302
[TBL] [Abstract][Full Text] [Related]
10. Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment.
Weibring K; Nord C; Ståhl O; Eberhard J; Sandberg K; Johansson H; Arver S; Giwercman A; Cohn-Cedermark G
Ann Oncol; 2019 Apr; 30(4):604-611. PubMed ID: 30798330
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor gene CAG and GGN repeat lengths as predictors of recovery of spermatogenesis following testicular germ cell cancer treatment.
Bogefors K; Giwercman YL; Eberhard J; Stahl O; Cavallin-Stahl E; Cohn-Cedermark G; Arver S; Giwercman A
Asian J Androl; 2017; 19(5):538-542. PubMed ID: 27873769
[TBL] [Abstract][Full Text] [Related]
13. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.
van Leeuwen FE; Stiggelbout AM; van den Belt-Dusebout AW; Noyon R; Eliel MR; van Kerkhoff EH; Delemarre JF; Somers R
J Clin Oncol; 1993 Mar; 11(3):415-24. PubMed ID: 8445415
[TBL] [Abstract][Full Text] [Related]
14. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy.
Khanal N; Ahmed SS; Kalra M; Miller TJ; Brames MJ; Stump TE; Monahan P; Hanna NH; Einhorn LH
Support Care Cancer; 2020 Jul; 28(7):3165-3170. PubMed ID: 31707501
[TBL] [Abstract][Full Text] [Related]
15. Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality.
Isaksson S; Bogefors K; Åkesson K; Egund L; Bobjer J; Leijonhufvud I; Giwercman A
Andrology; 2017 Sep; 5(5):898-904. PubMed ID: 28591464
[TBL] [Abstract][Full Text] [Related]
16. Hypogonadism risk in men treated for childhood cancer.
Romerius P; Ståhl O; Moëll C; Relander T; Cavallin-Ståhl E; Wiebe T; Giwercman YL; Giwercman A
J Clin Endocrinol Metab; 2009 Nov; 94(11):4180-6. PubMed ID: 19789207
[TBL] [Abstract][Full Text] [Related]
17. Medical treatment of advanced testicular cancer.
Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
[TBL] [Abstract][Full Text] [Related]
18. Role of organ-sparing surgery in germ cell tumors of the testis.
Yossepowitch O; Baniel J
Urology; 2004 Mar; 63(3):421-7. PubMed ID: 15028430
[No Abstract] [Full Text] [Related]
19. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
20. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
